

References

Bhole RP, Chikhale RV, Rathi KM (2023). Current biomarkers and treatment strategies in Alzheimer's disease: An overview and future perspectives. *IBRO Neurosci. Rep.* 30:8. doi: 10.1016/j.ibneur.2023.11.003

Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro D, Ghiglieri V (2023). Alpha-synuclein in Parkinson's disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction. *Cell Death & Disease* 14:176. doi.org/10.1038/s41419-023-05672-9

Chen S, Cai F, Wang J, Gu C, Wang G, Mao F, Yan J (2019). Salidroside protects SH-SY5Y from pathogenic α -synuclein by promoting cell autophagy via mediation of mTor/p70S6K signalling. *Mol. Med. Rep.* 20:529. doi.org/10.3892/mmr.2019.10285

Dravid A, Raos B, Svirskis D, O'Carroll SJ (2021). Optimised techniques for high-throughput screening of differentiated SH-SY5Y cells and application for neurite outgrowth assays. *Sci. Rep.* 11:23935. doi.org/10.1038/s41598-021-03442-1

Dias-Carvalho A, Sá SI, Carvalho F, Fernandes E, Costa VM (2024). Inflammation as common link to progressive neurological diseases. *Arch Toxicol* 98(1):95. doi: 10.1007/s00204-023-03628-8

Elsworthy RJ, Hill EJ, Dunleavy C, Aldred S (2022). The role of ADAM10 in astrocytes: Implications for Alzheimer's disease. *Front. Aging Neurosci.* 14:1056507. doi: 10.3389/fnagi.2022.1056507

Giri PM, Banerjee A, Ghosal A, Layek B (2024). Neuroinflammation in neurodegenerative disorders: Current knowledge and therapeutic implications. *Int. J. Mol. Sci.* 25:3995. doi: 10.3390/ijms25073995

Grotemeyer A, McFleder RL, Wu J, Wischhusen J, Ip CW (2022). Neuroinflammation in Parkinson's Disease-Putative pathomechanisms and targets for disease-modification. *Front. Immunol.* 13:878771. doi.org/10.3389/fimmu.2022.878771

Guimarães RP, Ribeiro DL, Dos Santos KB, Godoy LD, Corrêa MR, Padovan-Neto (2021). The 6-hydroxydopamine rat model of Parkinson's Disease. *J. Vis. Sci.* 176:e62923. doi:10.3791/62923

loghen OC, Ceafalan LC, Popescu BO (2023). SH-SY5Y Cell Line *In Vitro* Models for Parkinson Disease Research-Old Practice for New Trends. *J. Integr. Neurosci.* 22:20. doi.org/10.31083/j.jin2201020

Jain SK, Stevens CM, Margret JJ, Levine SN (2024). Alzheimer's Disease: A review of pathology, current treatments, and the potential therapeutic effect of decreasing oxidative stress by combined vitamin D and l-cysteine supplementation. *Antioxid. Redox. Signal.* 40:663. doi: 10.1089/ars.2023.0245

Li T, Feng Y, Yang R, Wu L, Li R, Huang L, Yang Q, Chen J (2018). Salidroside Promotes the Pathological α -Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells. *Front. Pharmacol.* 19:377. doi: 10.3389/fphar.2018.00377

Liu X, Liu Y, Ji S (2021). Secretases related to amyloid precursor protein processing. *Membranes* 11:983. doi: 10.3390/membranes11120983

Magistrelli L, Ferrari M, Furgiuele A, Milner AV, Contaldi E, Comi C, Cosentino M, Marino F (2021). Polymorphisms of dopamine receptor genes and Parkinson's Disease: Clinical relevance and future perspectives. *Int. J. Mol. Sci.* 22:3781. doi: 10.3390/ijms22073781

Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, Frank MJ, Jahanshahi M (2016). Motor symptoms in Parkinson's Disease: A unified framework. *Neurosci. Biobehav. Rev.* 68:727. doi: 10.1016/j.neubiorev.2016.07.010

Sharif A, Mamo J, Lam V, Al-Salami H, Mooranian A, Watts GF, Clarnette R, Luna G, Takechi R (2024). The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases. *Transl. Neurodegener.* 13:6. doi: 10.1186/s40035-024-00398-w

Thomas AL, Lehn MA, Janssen EM, Hildeman DA, Chougnet CA (2022). Naturally-aged microglia exhibit phagocytic dysfunction accompanied by gene expression changes reflective of underlying neurologic disease. *Sci. Rep.* 12:19471. <https://doi.org/10.1038/s41598-022-21920-y>

Voss T, Kost J, Mercer SP, Furtek C, Randolph C, Lines C, Egan MF, Cummings JL (2023). Progression from prodromal Alzheimer's disease to mild Alzheimer's disease dementia in the Verubecestat APECS study: Adjudicating diagnostic transitions. *J. Alzheimers Dis.* 92:341. doi: 10.3233/JAD-220836

Weaver DF (2023). Thirty Risk Factors for Alzheimer's Disease Unified by a Common Neuroimmune-Neuroinflammation Mechanism. *Brain Sci* 14(1):41. doi: 10.3390/brainsci14010041

Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q, Yang L, Xu P, Jiang X (2023). Inflammatory signalling pathways in the treatment of Alzheimer's disease with inhibitors, natural products and metabolites (Review). *Int. J. Mol. Med.* 52(5):111. doi: 10.3892/ijmm.2023.5314